To validate the efficacy of SIRT1‐targeted AD therapeutics under hyperglycemic conditions, a small molecule SIRT1 activator, resveratrol (Res),[8] and SIRT1 inhibitor, sirtinol (Sir), were used to activate and deactivate SIRT1, respectively. The gene discussed is SIRT1; the disease is Alzheimer disease.